膜增生性肾小球肾炎 中国就医指南

Membranoproliferative glomerulonephritis (MPGN) is a rare, chronic immune-mediated kidney disease characterized by histopathological changes including mesangial hypercellularity, thickening of the glomerular basement membrane, and duplication of the basement membrane ('double contours') visible on electron microscopy. Historically classified into types I, II (now termed dense deposit disease), and III, MPGN is now redefined based on underlying pathogenic mechanisms—primarily complement dysregulation (e.g., C3 nephropathy, autoantibodies against C3 convertase, or genetic mutations in complement regulators) or immune-complex deposition (often secondary to chronic infections like hepatitis C, autoimmune disorders such as SLE, or monoclonal gammopathies). The disease triggers inflammation and progressive injury to glomeruli, impairing filtration and leading to proteinuria, hematuria, hypertension, and declining glomerular filtration rate (GFR). Epidemiologically, MPGN accounts for <10% of primary glomerulonephritis cases in adults and is even rarer in children; incidence is estimated at 1–2 per million per year globally, with no strong gender predilection but a peak onset in adolescence and early adulthood. Risk factors include inherited complement pathway abnormalities (e.g., factor H, factor I, or MCP mutations), persistent viral infections (especially hepatitis C and less commonly HIV or EBV), autoimmune conditions (SLE, Sjögren’s syndrome), and lymphoproliferative disorders. Untreated or refractory MPGN carries high risk of progression to end-stage kidney disease (ESKD) within 10–15 years in up to 50% of patients. Quality of life is significantly impacted: patients often experience fatigue, edema-related discomfort, anxiety about renal decline, dietary and fluid restrictions, frequent clinic visits and lab monitoring, and psychosocial burden from long-term immunosuppression (e.g., corticosteroids, rituximab, eculizumab). Children may face growth delays and school absenteeism; adults report reduced work capacity, sexual dysfunction, and increased depression prevalence. Early diagnosis via kidney biopsy—including light, immunofluorescence, and electron microscopy—is critical, as treatment response varies substantially by etiology. Complement-targeted therapies have revolutionized management for primary C3-glomerulopathy–associated MPGN, while hepatitis C–related cases require antiviral therapy first. Despite advances, MPGN remains a challenging condition requiring multidisciplinary care involving nephrologists, immunologists, and pathologists to optimize outcomes and preserve kidney function.

# 膜增生性肾小球肾炎（MPGN）治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：初发、低风险病理分型（如C3肾病）、eGFR ≥60 mL/min/1.73m²、无显著新月体或间质纤维化者。

• •基础治疗：ACEI/ARB（如缬沙坦）+ 限盐低蛋白饮食，年药费 1,200–3,600元
• •免疫抑制治疗（需肾活检确诊）：

- 利妥昔单抗（375 mg/m²×4次）：单疗程 42,000–58,000元（含输液监护）

• •检查费：肾活检（含病理+免疫荧光+电镜）4,800–6,500元；补体C3/C4、PLA2R、CFH抗体等专项检测 1,200–2,600元/次

二、介入/核心治疗方案

适用人群：进展性蛋白尿（>3.5 g/d）、eGFR下降速率 >3 mL/min/年、伴血栓微血管病证据者。

• •血浆置换联合免疫抑制（每周3次×2周）：置换耗材+白蛋白+监测 22,000–35,000元/疗程
• •术前检查（含心脏超声、凝血四项、中心静脉置管评估）：2,800–4,200元

三、特殊复杂/晚期方案

耐药/复发/终末期（eGFR <15 mL/min）：

• •长期利妥昔单抗维持（每6个月1次）：年均 36,000–48,000元
• •合并ESRD者转入透析或肾移植评估：移植前评估费 15,000–22,000元（不含移植手术费）

四、方案快速选择指南

• •预算≤2万元/年：ACEI/ARB+生活方式干预（限用于轻症）
• •预算3–6万元/年：环磷酰胺方案（性价比首选）
• •预算≥5万元且高危复发：利妥昔单抗一线方案
• •eGFR<30且快速恶化：立即启动血浆置换+免疫抑制联合方案